Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1677428 | 0.94 | GCK (0.34) | ALDH1A1TP53CYP1A2CYP3A4MAPT | |
| SCHEMBL12734365 | 0.93 | GCK (0.32) | ALDH1A1TP53CYP1A2CYP3A4MAPT | |
| SCHEMBL12734363 | 0.91 | ADORA2B (0.33) | ALDH1A1 | |
| SCHEMBL12734326 | 0.90 | EGFR (0.32) | ALDH1A1TP53CYP1A2CYP3A4MAPT | |
| SCHEMBL13665708 | 0.90 | MAPT (0.31) | ALDH1A1MAPT | |
| SCHEMBL10240439 | 0.88 | P2RX3 (0.32) | — | |
| SCHEMBL1677907 | 0.88 | GCK (0.35) | — | |
| SCHEMBL1677578 | 0.86 | GCK (0.37) | ALDH1A1TP53CYP1A2CYP3A4MAPT | |
| SCHEMBL13665691 | 0.85 | GCK (0.33) | ALDH1A1 | |
| SCHEMBL1677518 | 0.85 | GCK (0.33) | ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8673942-B2 | Fused ring compounds and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-03-18 | — | — | US | disclosed |
| US-20110098297-A1 | FUSED RING COMPOUNDS AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098297-A1 | FUSED RING COMPOUNDS AND USE THEREOF | GCKR, GPR119, SLC5A1 | ALDH1A1 305/4885TP53 2626/4885CYP1A2 336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.